By Clinical Research Team  

December 27, 2024 | myTomorrows adds the ISRCTN registry to the clinical trial search functionality on its platform; Mission Bio collaborates with University of Miami on Multiple Myeloma (MM) at an unprecedented level of clonal detail; and more. 

myTomorrows announced the addition of the ISRCTN registry to the clinical trial search functionality on its platform. With this update, the AI-powered platform now sources from an even wider range of trusted, WHO-endorsed public registries, including clinicaltrials.gov, EudraCT, and now ISRCTN, providing one of the most comprehensive and unbiased search platforms in the world and covering clinical trials globally. Press release. 

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions on an innovative clinical trials program designed to match patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with a clinical trial specifically designed for the genetic signature of their disease. Sponsored by the National Cancer Institute (NCI), the myeloMATCH program aims to improve precision medicine. Patients in the myeloMATCH program undergo a bone marrow biopsy for diagnosis and screening. Depending on the genetic signature of their disease, they are assigned different trials specifically designed for their disease type. Press release. 

AmMax and The University of Texas MD Anderson Cancer Center announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer (CRC) and minimal residual disease (MRD) as well as those with MRD in other solid tumors. AmMax and MD Anderson will build upon preclinical discoveries made by MD Anderson researchers to evaluate the potential for AMB-066, which targets colony stimulating factor 1 receptor (CSF1R), in a Phase 2a proof-of-concept study, with patient enrollment anticipated to begin soon. Press release. 

Certis Oncology Solutions has commercially launched CertisOI Assistant, an innovative chatbot tool designed to enhance the efficiency and effectiveness of cancer research. This research tool leverages artificial intelligence/machine learning (AI/ML) and OpenAI’s ChatGPT language model to quickly provide researchers with insights into cancer models and drug response, bringing greater precision to early drug development decisions. The CertisOI Assistant works as a natural language intermediary for accessing the genomic and drug sensitivity characterization data associated with thousands of cancer research models, including Certis’ patient-derived xenograft (PDX) models, as well as public cancer cell lines from the Cancer Cell Line Encycolopedia (CCLE). By asking the CertisOI Assistant, users can convert query results into charts and graphs and download summary and detailed data for sharing. Press release. 

Baylor College of Medicine has received a $3.5 million grant from the National Human Genome Research Institute for the Making Genomics Accessible to Newborns in Texas (MAGNET) program to study how to overcome challenges in the implementation of in-patient genomic medicine in neonatal intensive care units in under-resourced healthcare communities. Advances in genomic medicine have improved diagnoses and care of sick newborn babies in neonatal intensive care units, but many medical centers across Texas lack access to resources necessary to provide this care. The MAGNET program aims to improve genetic diagnoses of sick newborns in NICUs at hospitals across underserved regions of Texas using low-cost whole genome and RNA sequencing technologies. Press release. 

Mission Bio collaborated with Dr. C. Ola Landgren, MD, PhD, head of one of the world’s leading myeloma computational and translational research laboratories. Dr. Landgren’s team at the University of Miami’s Sylvester Comprehensive Cancer Center worked to generate first-of-its-kind clinical data sets using Mission Bio’s Tapestri Single-cell DNA Multiple Myeloma Panel to examine Multiple Myeloma (MM) at an unprecedented level of clonal detail. The study is intended to unlock understanding of MM relapse. Press release.